Fasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes them. Elevated eosinophils are related to the cause and severity of asthma, as well as to asthma exacerbations. This mechanism of action differs from Nucala (mepolizumab; GlaxoSmithKline) and Cinqair (reslizumab; Teva), which bind to the IL-5 ligand, and this is proposed to lead to a faster onset of action.
LIST OF FIGURES
12 Figure 1: Fasenra for asthma – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Fasenra in asthma
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Fasenra in asthma
16 Figure 4: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Fasenra drug profile
7 Table 2: Fasenra Phase III trials in asthma
11 Table 3: Ongoing Phase III trials for Fasenra in asthma
17 Table 4: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.